Small Intestine Cancer Clinical Trial
Official title:
PillCam SB3 Registry for Development and Validation of Improved Algorithms for GI Pathologies Detection
Observational, Multicenter, Post-market, Minimal risk, Prospective data collection of PillCam SB3 videos (including PillCam reports) and raw data files and optional collection of Eneteroscopy reports
Up to 8000 PillCam SB3 videos (including PillCam reports) and raw data files will be collected in up to 50 medical centers in the US. Study duration is up to 7 years from IRB approval. Medical center study sites will provide relevant videos (including PillCam reports) and raw data from patients who underwent SB3 procedures. Per patient demographic data will be also collected to provide a description of the study population characteristics and disposition. Additional Standard of care data collection might be performed (optional). This data will include a de-identified Eneteroscopy report, from patients enrolled to the study and referred to Eneteroscopy procedure (all types of Eneteroscopies), following findings identified during the PillCamTM SB procedure, as part of the standard of care procedure. This data might be collected retrospectively for enrolled patients who underwent an Eneteroscopy procedure. The de-identified reports will be used by MDT GI research and development team to further develop and validated SB capsule localization. Study subjects will not undergo any additional procedures, nor will their diagnosis and subsequent treatment pathway be changed for the purpose of the registry. The data will be used by MDT GIs research and development team for the development and validation of improved and new detectors in the PillCam software. The videos (including PillCam reports) and raw data files will be de-identified at the medical center by representatives who are authorized and delegated to review medical records, prior to providing them to the sponsor. All data in the study- videos, reports, raw data files and demographic information will be de-identified in a manner that is untraceable by the sponsor clinical study team members. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00903396 -
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
|
Phase 2 | |
Terminated |
NCT00896467 -
Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy
|
N/A | |
Completed |
NCT00897923 -
Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma
|
N/A | |
Completed |
NCT00003993 -
Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma
|
Phase 1 | |
Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
Completed |
NCT00956475 -
Quality of Life in Younger Leukemia and Lymphoma Survivors
|
Phase 1 | |
Completed |
NCT00646139 -
KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment
|
Phase 1 | |
Active, not recruiting |
NCT00410462 -
Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma
|
Phase 2 | |
Completed |
NCT00562380 -
AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma
|
Phase 1 | |
Completed |
NCT00049400 -
S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction
|
Phase 1 | |
Completed |
NCT00049699 -
VNP40101M in Treating Patients With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT00049712 -
Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma
|
Phase 1 | |
Completed |
NCT00006348 -
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
|
Phase 3 | |
Completed |
NCT00004189 -
Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT00005804 -
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Completed |
NCT00004904 -
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
|
Phase 1 | |
Completed |
NCT00004895 -
Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery
|
Phase 2 | |
Completed |
NCT00019019 -
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
|
Phase 1 | |
Withdrawn |
NCT00621036 -
Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma
|
Phase 2 | |
Completed |
NCT00987766 -
Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer
|
Phase 1 |